MDI reaffirms partnership with Lundbeck

Collaboration and commitment are hallmarks of a thriving long-term business relationship. Building on a decade-long partnership, Metro Drug Inc (MDI) and H. Lundbeck A/S (Lundbeck) have inked an agreement to continue distributing their products in the Philippines over the next five years.

A global pharmaceutical company, Lundbeck is committed to improving the quality of life of individuals living with psychiatric and neurological disorders. To help treat these patients, the company invests heavily in R&D to produce, market and sell pharmaceuticals that treat disorders in the central nervous system. These include depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and insomnia.

“We have been working with Lundbeck since 2007 and share their enthusiasm in growing their business. We are confident that our close working relationship will continue to help improve access to quality healthcare in the Philippines,” said Jannette Jakosalem, Chief Executive MDI.

Joan Alvarez, Lundbeck Philippines President added, “Joining forces with MDI’s expertise and wide reach, makes this a winning partnership that will result in new treatment solutions being made available to individuals suffering from brain diseases in the Philippines.”